Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
66 hedge funds and large institutions have $30.5M invested in Asterias Biotherapeutics Inc. Series A in 2017 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 7 closing their positions.
72% more call options, than puts
Call options by funds: $246K | Put options by funds: $143K
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
0% more funds holding
Funds holding: 66 → 66 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less capital invested
Capital invested by funds: $40.6M → $30.5M (-$10.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$414K |
| 3 |
State Street
Boston,
Massachusetts
|
+$148K |
| 4 |
FM
Family Management
New York
|
+$113K |
| 5 |
Millennium Management
New York
|
+$90.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$224K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$134K |
| 3 |
Morgan Stanley
New York
|
-$130K |
| 4 |
Citigroup
New York
|
-$87.9K |
| 5 |
Squarepoint
New York
|
-$72K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CFA
51
CT Financial Advisors
Chadds Ford,
Pennsylvania
| $24 | – | – | – |
|
|
OAM
52
Oxford Asset Management
Oxford,
United Kingdom
| – | -$224K | -48,790 | Closed |
|
|
53
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$134K | -34,373 | Closed |
|
|
54
Squarepoint
New York
| – | -$72K | -15,690 | Closed |
|
55
Two Sigma Investments
New York
| – | -$62K | -13,371 | Closed |
|
56
JP Morgan Chase
New York
| – | -$53K | -11,415 | Closed |
|
|
AIM
57
Acrospire Investment Management
Chicago,
Illinois
| – | -$28K | -6,101 | Closed |
|
|
AG
58
Advisor Group
Phoenix,
Arizona
| – | -$159 | -41 | -46% |
|
|
DADC
59
D.A. Davidson & Co
Great Falls,
Montana
| – | +$16 | +4 | New |
|
60
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | +$31 | +8 | New |
|
|
PFO
61
Pathstone Family Office
Englewood,
New Jersey
| – | +$159 | +41 | New |
|
62
Barclays
London,
United Kingdom
| – | +$525 | +135 | +255% |
|
AST Hedge Fund Activity: Q1 2017 in Review
66 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2017, worth a combined $30.5M — down 25% from $40.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new AST positions and 7 closed out — a net gain of 4 holders — while 18 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $4.36M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $224K sold.
- 66 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $30.5M of Asterias Biotherapeutics Inc. Series A stock for Q1 2017, down 25% quarter-over-quarter.
- 11 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2017 and 7 closed out, a net change of +4 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q1 2017 was BlackRock, an estimated $4.36M added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2017 was Oxford Asset Management, an estimated $224K sold.
Based on aggregated 13F filings for Q1 2017.